Infusion-related reactions to infliximab (remicade®) in patients with rheumatoid arthritis:: Relationship to dose, anti-histamine pre-treatment and infusion number

被引：0
|
作者：
Wasserman, MJ [1 ]
Weber, DA [1 ]
Guthrie, JA [1 ]
Mitroi, E [1 ]
Bykerk, V [1 ]
Lee, P [1 ]
Keystone, EC [1 ]
机构：
[1] Univ Toronto, Mt Sinai Hosp, Ctr Adv Therapeut, Toronto, ON M5G 1X5, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2003年 / 30卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1888 / 1888
页数：1
相关论文
共 50 条
  • [41] Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma?
    Park, Sang-Gon
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (04): : 775 - 776
  • [42] Rates and predictors of infusion-related reactions in patients receiving standard versus prolonged infusion of rabbit anti-thymocyte globulin for hematopoietic stem cell transplantation, a retrospective analysis
    Abdullah S. Al Saleh
    Abdulrahman I. Alghamdi
    Mohsen Alzahrani
    Bader Alahmari
    Ayman Alhejazi
    Ahmed Alaskar
    Husam Alsadi
    Suha Alkhraisat
    Inaam Shehab-Eddine
    Moussab Damlaj
    Bone Marrow Transplantation, 2022, 57 : 1201 - 1203
  • [43] Rates and predictors of infusion-related reactions in patients receiving standard versus prolonged infusion of rabbit anti-thymocyte globulin for hematopoietic stem cell transplantation, a retrospective analysis
    Al Saleh, Abdullah S.
    Alghamdi, Abdulrahman I.
    Alzahrani, Mohsen
    Alahmari, Bader
    Alhejazi, Ayman
    Alaskar, Ahmed
    Alsadi, Husam
    Alkhraisat, Suha
    Shehab-Eddine, Inaam
    Damlaj, Moussab
    BONE MARROW TRANSPLANTATION, 2022, 57 (07) : 1201 - 1203
  • [44] Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
    Jeffrey R. Curtis
    Soumya D. Chakravarty
    Shawn Black
    Shelly Kafka
    Stephen Xu
    Wayne Langholff
    Dennis Parenti
    Andrew Greenspan
    Sergio Schwartzman
    Rheumatology and Therapy, 2021, 8 : 1551 - 1563
  • [45] Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
    Curtis, Jeffrey R.
    Chakravarty, Soumya D.
    Black, Shawn
    Kafka, Shelly
    Xu, Stephen
    Langholff, Wayne
    Parenti, Dennis
    Greenspan, Andrew
    Schwartzman, Sergio
    RHEUMATOLOGY AND THERAPY, 2021, 8 (04) : 1551 - 1563
  • [46] The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure
    Krintel, Sophine B.
    Grunert, Veit Peter
    Hetland, Merete L.
    Johansen, Julia S.
    Rothfuss, Matthias
    Palermo, Giuseppe
    Essioux, Laurent
    Klause, Ursula
    RHEUMATOLOGY, 2013, 52 (07) : 1245 - 1253
  • [47] Impact of pre-medication on the frequency of infusion-related reactions (IRRs) and efficacy in patients (pts) treated with cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): the MABEL study
    Wilke, H.
    Siena, S.
    Thaler, J.
    Adenis, A.
    Preusser, P.
    Bridgewater, J.
    Gasparini, G.
    Esser, R.
    Loos, A.
    Glynne-Jones, R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 243 - 243
  • [48] Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study
    Naghmeh Abbasi Kasbi
    F. Ghadiri
    M. A. Sahraian
    M. A. Nahayati
    A. Naser Moghadasi
    H. Ghalyanchi Langroodi
    M. Poursadeghfard
    S. Hosseini
    H. Heidari
    S. M. Baghbanian
    H. Kamali
    Z. Ameli
    S. Shahmohammadi
    S. Navardi
    Acta Neurologica Belgica, 2024, 124 : 205 - 212
  • [49] An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
    Arie E. van der Bijl
    Ferdinand C. Breedveld
    Christian E. Antoni
    Joachim R. Kalden
    Sonja Kary
    Gerd R. Burmester
    Christina Beckmann
    Kristina Unnebrink
    Hartmut Kupper
    Clinical Rheumatology, 2008, 27 : 1021 - 1028
  • [50] An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
    van der Bijl, Arie E.
    Breedveld, Ferdinand C.
    Antoni, Christian E.
    Kalden, Joachim R.
    Kary, Sonja
    Burmester, Gerd R.
    Beckmann, Christina
    Unnebrink, Kristina
    Kupper, Hartmut
    CLINICAL RHEUMATOLOGY, 2008, 27 (08) : 1021 - 1028
12345